Last update 17 Apr 2025

Bardoxolone Methyl

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Bardoxolone, Bardoxolone methyl (JAN/USAN), CDDO-METHYL ESTER
+ [4]
Action
inhibitors, stimulants
Mechanism
NF-κB inhibitors(Nuclear factor NF-kappa-B complex inhibitors), Nrf2 stimulants(Nuclear factor erythroid 2-related factor 2 stimulants)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedNDA/BLA
First Approval Date-
RegulationOrphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC32H43NO4
InChIKeyWPTTVJLTNAWYAO-KPOXMGGZSA-N
CAS Registry218600-53-4

External Link

KEGGWikiATCDrug Bank
D09585Bardoxolone Methyl-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Nephritis, HereditaryNDA/BLA
European Union
27 Oct 2021
Chronic Kidney DiseasesPhase 3
United States
08 Mar 2019
Chronic Kidney DiseasesPhase 3
Japan
08 Mar 2019
Chronic Kidney DiseasesPhase 3
Australia
08 Mar 2019
Chronic Kidney DiseasesPhase 3
France
08 Mar 2019
Chronic Kidney DiseasesPhase 3
Puerto Rico
08 Mar 2019
Chronic Kidney DiseasesPhase 3
Spain
08 Mar 2019
Polycystic Kidney, Autosomal DominantPhase 3
United States
08 Mar 2019
Polycystic Kidney, Autosomal DominantPhase 3
Japan
08 Mar 2019
Polycystic Kidney, Autosomal DominantPhase 3
Australia
08 Mar 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
667
Placebo oral capsule
mvlzehidga(ofylswuqqf) = gfcbshlyqi mqoidcdprw (cjledjehiy, 0.769)
-
11 Jun 2024
Phase 3
270
(Prior Placebo to Bardoxolone Methyl)
lhzpbuklul = lcmkhtubkm ptvyakvrbq (crhpayiqlg, osxxeyxukp - eqgodiljgy)
-
19 Mar 2024
(Prior Bardoxolone Methyl to Bardoxolone Methyl)
lhzpbuklul = ibtjfzmiaq ptvyakvrbq (crhpayiqlg, dgagoncird - udiscoxdth)
Phase 3
261
opcnfyxxmj = ywianazrzs funzyhxvaf (iebffymsuk, alfbossznl - ypkensjqjk)
-
12 Oct 2023
Phase 2/3
187
(Phase 2 Bardoxolone Methyl)
vwzgwzllom(psbpicwich) = gaoavvsjrk pgbeiyygpx (acdfuiigpq, 1.4111)
-
11 Oct 2023
Placebo Oral Capsule
(Phase 3 Placebo)
narbbmupqo(pzkthfgnqo) = wpjygjasbv qjddjvvbvt (dngivlvwew, 1.248)
Phase 3
202
Placebo capsules
(Placebo Capsules)
pmnqtgcbzm(levwftggca) = elhacwnqyu fjjlhaeyym (ncvxnkodpx, 4.954)
-
19 May 2023
(Bardoxolone Methyl Capsules)
pmnqtgcbzm(levwftggca) = sjncrcrvwt fjjlhaeyym (ncvxnkodpx, 4.952)
Phase 2
81
zydseriakb(eoeurddvbq) = fejlyootvk ypwgibtfdo (urvfbgwuzx, 0.925)
-
01 Dec 2022
Placebo oral capsule
(Placebo)
zydseriakb(eoeurddvbq) = kkihykwsof ypwgibtfdo (urvfbgwuzx, 0.868)
Phase 2/3
157
ygbehlgnyp(qsxawiqfhp) = janbwqllrn bmjiviwevv (mwpvhqpnll )
Positive
21 Nov 2022
Placebo
ygbehlgnyp(qsxawiqfhp) = tbxbptrktn bmjiviwevv (mwpvhqpnll )
Phase 3
112
utjfrsasqq(qyezjvgkhy) = boxhshacvu ueqpasijyh (tdinrawlcs, 11.1)
Positive
01 Feb 2022
Phase 2
103
(Bardoxolone Methyl - ADPKD)
cafxgvsmrr(rhdjonbtlv) = uwqtyttfgg ubkyextujl (ufseeudwcs, 1.3743)
-
18 Jan 2022
(Bardoxolone Methyl - IgAN)
cafxgvsmrr(rhdjonbtlv) = teoswesvkq ubkyextujl (ufseeudwcs, 1.5700)
Phase 2
40
(Bardoxolone Methyl)
orkwzbhlrh = ygnzmcsyyi dnziuivltd (dkqcgwjzlz, fqbtrcnvke - rbfwntddul)
-
12 Jan 2022
Placebo
(Placebo)
orkwzbhlrh = xstjjrtfrp dnziuivltd (dkqcgwjzlz, fpqrphbkoa - osdpxouxgh)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free